Loading organizations...
VALANX Biotech develops advanced protein conjugation technologies, centered on its GoldenSite™ platform. This system facilitates highly precise, site-specific protein modification via rapid click-chemistry for exceptional conjugate homogeneity. The streamlined process requires no catalysts, optimizing next-generation treatments by enhancing therapeutic windows and de-risking clinical development.
The company was co-founded in March 2017 by CEO Michael Lukesch and CBO Georg Altenbacher. VALANX Biotech emerged from Michael Lukesch's doctoral research at the Technical University of Graz, where his pioneering work on site-specific protein conjugation illuminated its potential for biotherapeutic advancement.
VALANX Biotech serves developers of complex biotherapeutics like antibody-drug conjugates and vaccines, aiming to improve drug efficacy and patient safety. The company envisions providing patients with more potent therapies and fewer adverse effects, promoting sustained treatment adherence. Its mission is to create impactful treatments through scientific innovation.
VALANX Biotech has raised $2.1M across 2 funding rounds.
VALANX Biotech has raised $2.1M in total across 2 funding rounds.
VALANX Biotech has raised $2.1M across 2 funding rounds. Most recently, it raised $2.0M Seed in November 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2023 | $2M Seed | — | Elaia Partners, SOSV | Announced |
| Apr 1, 2017 | $100K Seed | — | Elaia Partners, SOSV | Announced |
VALANX Biotech has raised $2.1M in total across 2 funding rounds.
VALANX Biotech's investors include Elaia Partners, SOSV.
VALANX Biotech is a Vienna-based biotechnology company developing GoldenSite™, a patented synthetic biology platform for site-specific protein conjugation that enables precise, high-efficiency attachment of drugs to proteins like antibodies.[1][2][3] This technology primarily targets antibody-drug conjugates (ADCs) for cancer and other diseases, serving biotech developers and patients by improving therapeutic windows—allowing higher dosing with reduced toxicity, better pharmacokinetics, and fewer side effects—while de-risking clinical development through optimized biophysical profiles.[3][4] The company is advancing an internal pipeline including VLX-301 for pancreatic cancer, VLX-101 for autoimmune diseases, and VLX-201 for neoplasms, all in discovery stage, with recent momentum from winning the RESI Boston Innovator's Pitch Challenge 2024 and forming a high-profile Board of Directors.[5][4]
VALANX Biotech emerged from research at the Technical University of Graz, where founder and CEO Michael Lukesch developed the core technology during his PhD on synthetic biology and genetic code expansion for incorporating proprietary synthetic amino acids into proteins.[2] Recognizing the potential to create superior biologics via precise conjugation using click chemistry in E. coli and CHO cells, Lukesch spun out the company to commercialize it.[1][2] Early traction came from investor interest amid converging advances in click chemistry and CRISPR, plus industry validation; xista Ventures invested, citing the "perfect storm" of demand and technology.[2] Pivotal moments include Pascal Deschatelets (CTO of Apellis Pharmaceuticals) joining the board in 2022 and the 2024 RESI Boston win, which boosted U.S. investor networks.[2][5]
VALANX stands out in protein conjugation through these key advantages:
VALANX rides the ADC market boom, where demand for next-generation conjugates surges due to limitations in current therapies like off-target toxicity and high discontinuation rates—projected to grow amid oncology and autoimmune needs.[3][4][5] Timing aligns with synthetic biology advances (genetic code expansion, click chemistry, CRISPR) enabling precise bioconjugation, positioning VALANX to unlock larger design spaces for safer, more potent biologics.[2] Favorable forces include AI-driven optimization and U.S. expansion via pitch wins, influencing the ecosystem by offering a low-cost platform for developers to de-risk pipelines and accelerate from discovery to clinic.[3][5][6]
VALANX is poised for clinical entry, with its matured GoldenSite™ platform and discovery pipeline targeting high-need areas like pancreatic cancer and autoimmunity; next steps include upstream process scaling, tech transfer to CDMOs, and partnerships leveraging its new board's commercialization expertise.[4][6] Trends like AI in drug design and ADC evolution will amplify its edge, potentially expanding influence through licensing or co-development deals in a validating U.S. market.[3][5] As a university spin-out supercharging proteins, VALANX exemplifies how synthetic biology unlocks boundary-pushing therapies for real patient impact.[1][3]
